Castle Biosciences
CSTL
126 hedge funds and large institutions have $443M invested in Castle Biosciences in 2020 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 52 increasing their positions, 16 reducing their positions, and 7 closing their positions.
543% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 7
225% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 16
102% more capital invested
Capital invested by funds: $219M → $443M (+$224M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
42% more funds holding
Funds holding: 89 → 126 (+37)
17.87% more ownership
Funds ownership: 42.81% → 60.68% (+18%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $339K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$15.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11M |
| 3 |
Morgan Stanley
New York
|
+$10.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.4M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$3.31M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$2.18M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$882K |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$874K |
| 5 |
3C
361 Capital
Denver,
Colorado
|
-$733K |
CSTL Hedge Fund Activity: Q2 2020 in Review
126 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q2 2020, worth a combined $443M — up 102% from $219M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new CSTL positions and 7 closed out — a net gain of 38 holders — while 52 added to existing stakes and 16 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $15.1M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $3.31M sold.
- 126 institutional investors held Castle Biosciences (CSTL) as of Q2 2020, up from 89 in Q1 2020.
- Funds reported $443M of Castle Biosciences stock for Q2 2020, up 102% quarter-over-quarter.
- 45 funds opened new Castle Biosciences positions in Q2 2020 and 7 closed out, a net change of +38 holders.
- The largest Castle Biosciences buyer in Q2 2020 was Wasatch Advisors, an estimated $15.1M added.
- The largest Castle Biosciences seller in Q2 2020 was Pura Vida Investments, an estimated $3.31M sold.
Based on aggregated 13F filings for Q2 2020.